ABSTRACT
of Ac-Dex and CUR in a solution of tetrahydrofuran (THF) and acetone. We hypothesize 146 that upon pulmonary administration, the nCmP will deposit in the deep lung, decompose 147 into free NP, and facilitate the sustained release of drug to the targeted site, while the MP 148 will remain the original size after deposition in the deep lung region. A schematic of the 149 described particle preparation and design is shown in Figure 1 . Overall, the goal of the 150 described research was the initial development and physicochemical characterization of 151 dry powder Ac-Dex aerosol particle systems with the potential for effective delivery of 
MATERIALS AND METHODS

156
Materials
157
Dextran from Leuconostoc mesenteroides (9000-11000 MW), pyridinium p- 
Synthesis and NMR Analysis of Acetalated Dextran (Ac-Dex)
169
Ac-Dex was synthesized as described previously (Bachelder et al., 2008) with 170 minor modifications. 1 g of lyophilized dextran and 25 mg of PPTS were dissolved in 10 171 mL of anhydrous DMSO. The resulting solution was reacted with 5 mL of 2-MOP under 172 nitrogen gas for 5 minutes to prepare Ac-Dex with a rapid degradation rate (Ac-Dex-173 5min) or for 3 hours to prepare Ac-Dex with a slower degradation rate (Ac-Dex-3h). The 174 reaction was quenched with 1 mL of TEA. The reaction mixture was then precipitated in 175 basic water (water and TEA, pH 9), vacuum filtered, and lyophilized (−50 °C, 0.023 176 mbar) for 24 hours to yield a solid product.
177
The cyclic-to-acyclic (CAC) ratio of acetal coverage and degrees of total acetal to acetone, methanol, and the carbon ring of dextran, the CAC ratio of acetal coverage 184 and degrees of total acetal coverage per 100 glucoses were determined.
186
Formation of CUR-Loaded Ac-Dex Nanoparticles (CUR NP)
187
Curcumin-loaded nanoparticles (CUR NP) were prepared via an oil/water 188 emulsion solvent evaporation using Ac-Dex-5min, Ac-Dex-3h, or a mixture of both types
189
of Ac-Dex (50 % w/w). 49 mg of Ac-Dex and 1 mg of CUR were dissolved in 1 mL of
190
DCM over an ice bath, establishing the organic phase. The aqueous phase was comprised 9 of 6 mL of 3% PVA in PBS and was added to the organic phase. desiccator at −20°C. The resulting MP were: MP-5min (from Ac-Dex-5min), MP-3h
228
(from Ac-Dex-3h), and MP-h (from 50 wt% Ac-Dex-5min and 50 wt% Ac-Dex-3h). 
Tapped Density Evaluation of nCmP and MP
252
The tapped density of the particles was measured as described previously with where ρ is the tapped density, m is the particle mass, and V is the volume occupied by the was applied to test the applicability of the described release models. In vitro aerosol dispersion performance of nCmP and MP was evaluated using a CUR-MP and CUR-nCmP ( Figure S1 ). The fine particle fraction (FPF), respirable 343 fraction (RF), and emitted dose (ED) were calculated as follows:
mass of particles on Stages 2 through 7 Fine particle fraction (FPF) = 100% (5) initial particle mass loaded into capsules mass of particles on Stages 2 through 7 Respirable fraction (RF) = total ´ 100% (6) particle mass on all stages initial mass in capsules -final mass remaining in capsules Emitted dose (ED) = 100% (7) (Table S1 ). The spray drying process had no influence on the CUR loading and EE for 426 the nCmP systems (p < 0.05), which indicates that the drug loading of nCmP systems can 427 be determined during NP preparation.
428
Results of the in vitro release of CUR from both nCmP and MP systems in 429 modified phosphate (pH 7.4) and acetate (pH 5) buffers at physiological temperature
430
(37°C) are reported in Figure 3 as the percentage of cumulative drug released over time.
431
As shown in and local cytotoxicity (Meenach et al., 2012) .
441
In addition, the nCmP systems exhibited faster release than the MP systems,
442
which is likely due to the larger surface area available in the nano-sized delivery systems.
443
Upon reaching an aqueous environment, the nCmP dissociate into nanoparticles with 444 large surface areas and a PVA coating that facilitates particle dispersity, while the MP 445 may agglomerate due to their highly hydrophobic, uncoated surfaces. As a result, the 446 nCmP systems undergo faster polymer degradation and drug diffusion, resulting in a 447 faster release of payloads than MP at both acidic and physiologic pH.
448
Particles comprised of Ac-Dex-3h exhibited slower release rates than those 449 comprised of Ac-Dex-5min, indicating that the drug release rate can be controlled by the 
466
In order to further illustrate the mechanism of drug release of Ac-Dex particles,
467
we fitted the CUR release data to several commonly utilized drug release models, compared with other models, indicating that the drug release profiles of all Ac-Dex
478
The residual water content of CUR nCmP and MP is shown in confirmed those from DSC thermograms, which show that raw CUR was converted to 536 amorphous forms during the particle manufacturing process.
538
In Vitro Aerosol Dispersion Performance Using Next Generation Impactor (NGI)
539
In vitro aerosol dispersion performance properties of the nCmP were evaluated Table 2 ), calculated using the geometric diameter and tapped density, was 550 lower than the experimental MMAD. This discrepancy is likely due to particle 551 agglomeration, which increased the geometric size of the dry powder particulates. All of 
CONCLUSIONS
562
Two types of pulmonary delivery systems were successfully formulated using Ac-
563
Dex with two different degradation rates. The resulting CUR MP were wrinkled spheres
564
(approximately 1 µm), while nCmP were similar in size with wrinkled surfaces that 565 showed the presence of nanoparticles. The variations in the drug release rates from the 566 Ac-Dex particles were influenced by the Ac-Dex reaction time, ratio of two types of Ac-567 Dex, and the particle size, which could be easily tuned during the manufacturing process.
568
The pH value of the environment also had a significant influence on the release profiles, allowing the Ac-Dex particles to release the payload in a controlled fashion. 206.1 ± 1.3 0.03 ± 0.03 -7.0 ± 1.6 nCmP-5min
199.3 ± 1.3 0.09 ± 0.02 -14.5 ± 1.0 nCmP-h 210.2 ± 2.5 0.07 ± 0.01 -13.3 ± 1.9 nCmP-3h 213.5 ± 2.4 0.02 ± 0.00 -11.2 ± 1.6 MP (mean ± standard deviation, n = 3). 
S.1 Drug Release Model Descriptions
808
The drug release data of the particle systems was fitted to several relevant models determine the parameters that minimize the sum of squares of the residues of the model.
814
The models, equations, and their corresponding parameters are as follows:
First order model:
where M t is the amount of drug released at time t, M 0 is the initial amount of drug in the 819 solution, and K is the first order release constant.
821
Weibull model:
where m is the accumulated fraction of the drug released at time t, a is the scale 824 parameter, which defines the time scale of the process, T i is the location parameter, which 825 represents the lag time before the onset of the dissolution or release process, and b is the 826 shape parameter, which characterizes the shape of release curve. Baker's model:
where M t is the amount of drug released in time t, P 0 is the drug permeability, A is the 859 total area of the particle, C 0 is the drug concentration at the initial time, and k is the first-860 order rate constant of bond cleavage of the polymer carrier. 
